PMID- 34703259
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 14
DP  - 2021
TI  - Enhanced Expression of miR-34c in Peripheral Plasma Associated with Diabetic Foot 
      Ulcer in Type 2 Diabetes Patients.
PG  - 4263-4273
LID - 10.2147/DMSO.S326066 [doi]
AB  - OBJECTIVE: To explore the correlation between the expression of miR-34c in 
      peripheral blood of patients with type 2 diabetes mellitus (T2DM) and the onset 
      of diabetic foot ulcer (DFU) and diabetic foot osteomyelitis (DFO). METHODS: 
      Sixty newly diagnosed patients with T2DM without DFU (T2DM group), 112 T2DM 
      patients with DFU (DFU group) and 60 controls with normal glucose tolerance (NC 
      group). The DFU group patients were subdivided into DFO (n=64) and NDFO (n=48) 
      groups. Quantitative real-time PCR (qRT-PCR) method was used to determine miR-34c 
      expression levels in the peripheral blood of subjects to analyze the clinical 
      characteristics of DFU and DFO risk factors. RESULTS: MiR-34c expression level in 
      the T2DM group was marked higher than the NC group [2.99 (1.45-6.22) vs 1.01 
      (0.89-1.52)] (P < 0.05). However, the expression level of miR-34c in the DFU 
      group was significantly higher than the T2DM group [9.65 (6.15-18.63) vs 2.99 
      (1.45-6.22)] (P < 0.01). Compared with the NDFO group, the expression level of 
      miR-34c in the DFO group was also obviously increased [13.46 (8.89-19.11) vs 6.02 
      (5.93-14.72)] (P < 0.01). The expression level of miR-34c in DFU patients was 
      positively correlated with the amputation rate of foot ulcers (P=0.030) and was 
      negatively correlated with the healing rate of foot ulcers after eight weeks 
      (P=0.025). Multifactorial logistic regression analysis showed that increased 
      expression of miR-34c was an independent risk factor for DFU and DFO 
      (OR(DFU)=3.47, OR(DFO)=4.25, P < 0.01). Meanwhile, the ROC curve analysis 
      indicated that the AUC of miR-34c for the diagnosis of DFU and DFO was 0.803 and 
      0.904, the optimum sensitivity being was 100% and 98.7%, the optimum specificity 
      was 98.4% and 98.4%, respectively. CONCLUSION: The increased expression of 
      miR-34c in peripheral blood of T2DM patients is closely related to the 
      occurrence, development and prognosis of DFU and DFO.
CI  - (c) 2021 Wu et al.
FAU - Wu, Tingting
AU  - Wu T
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Xie, Dandan
AU  - Xie D
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Zhao, Xiaotong
AU  - Zhao X
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Xu, Murong
AU  - Xu M
AUID- ORCID: 0000-0002-3101-0725
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Luo, Li
AU  - Luo L
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Deng, Datong
AU  - Deng D
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
FAU - Chen, Mingwei
AU  - Chen M
AUID- ORCID: 0000-0002-8439-0469
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, 230032, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20211015
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8526515
OTO - NOTNLM
OT  - diabetic foot
OT  - diabetic foot osteomyelitis
OT  - miRNAs
OT  - type 2 diabetes
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/10/28 06:00
MHDA- 2021/10/28 06:01
PMCR- 2021/10/15
CRDT- 2021/10/27 07:04
PHST- 2021/06/22 00:00 [received]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/10/27 07:04 [entrez]
PHST- 2021/10/28 06:00 [pubmed]
PHST- 2021/10/28 06:01 [medline]
PHST- 2021/10/15 00:00 [pmc-release]
AID - 326066 [pii]
AID - 10.2147/DMSO.S326066 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2021 Oct 15;14:4263-4273. doi: 10.2147/DMSO.S326066. 
      eCollection 2021.